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The public health achievements of immunisation are well-recognised, with
remarkable success in eradication or control of diseases such as smallpox, polio,
pertussis, measles, mumps, rubella, hepatitis B, tetanus, diphtheria and Haemophilus
influenzae type b (Hib).1, 2 Further health benefits are expected. Novel technologies
have enabled development of vaccines against a widening array of diseases including
human papillomavirus (HPV), and herpes zoster.3 Vaccines against pathogens as
diverse as human immunodeficiency virus, malaria, tuberculosis, herpes simplex
virus, dengue fever, Ross River virus, Staphylococcus aureus and Clostridium difficile
are at varying stages of development.3 Existing programs continue to be updated
with new combination vaccines, such as measles-mumps-rubella-varicella (MMRV),
or vaccines for a wider number of disease strains, such as 13-valent pneumococcal
vaccine, and novel delivery systems are being tested.3
The control of infectious diseases that immunisation has achieved, along with the
increased number of vaccines offered in childhood schedules, have brought with
them new challenges for how we communicate the benefits and risks of
immunisation. This article considers the ethical and policy implications of
developments in immunisation, for both individual consent and societal involvement
in decision making, and offers some recommendations for how policy and practices
can meet these challenges.
1. Individual consent
In western society, it is broadly accepted in ethics, law and health care that
individuals should be able to make decisions about their own health care in ways
that reflect their needs, wishes and values. In health care, the provision of consent is
the means by which people actualise their autonomy (self-rule or selfdetermination), by authorising what happens to them and who touches them.4 For
consent to be valid, patients (or their parents) must be competent to make the
decision, sufficiently informed, understand the information provided and be able to
act freely and voluntarily.5
The contemporary environment in which immunisation programs are administered
presents a series of challenges to ensuring valid consent. One of these lies in
managing the volume of information about each vaccine as schedules become
increasingly ‘crowded’, and a second lies in accommodating different lay and public
health views about the relative merits of immunisation where the risk–benefit ratios
of immunisation are less stark and/or less apparent.
Managing the volume of information
There is an increasing number of vaccines recommended for children as part of
national programs. The Australian National Immunisation Program Schedule
currently has 6 recommended vaccines against 13 diseases. This compares with 3
vaccines against 9 diseases prior to 1994. Public and immunisation provider concerns
about this increase are evident; up to one-third of parents and health professionals
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feel that children receive too many vaccines6, 7 and there is evidence that parents are
becoming increasingly selective about whether their child has all vaccines on offer
and they tend to be more wary of newer vaccines.8, 9
Ensuring valid consent for each new vaccine is increasingly difficult as this requires
that, for each vaccine, parents must be provided with sufficient information about
their material risks and benefits. This is particularly the case for parents of children
aged under 5 years (given the sheer number of recommended vaccines) and for
parents of medically at-risk and Indigenous children who have more vaccines
recommended for them. Health professionals must also contend with scientific
uncertainty about some of the rare but serious diseases associated with vaccination
where causation is difficult to establish. They must also manage the volume of
information potentially required and their own sometimes limited knowledge of
vaccines.10 Given these challenges, it is hardly surprising that studies suggest that in
practice the ethical and legal standards of consent are often not met. 11, 12
Some have suggested that this results from the absence of clear and consistent
policies and processes for risk communication surrounding immunisation. Health
professionals and consumers have argued that the absence of sufficient, rigorous
and consistent information about the relative risks and benefits of immunisation
undermines public trust in immunisation (as a whole) and undermines the ability of
individuals to make informed decisions.13 10 This criticism has been most keenly
expressed when genuine vaccine safety signals arise or when a parent believes they
were insufficiently warned about a vaccine reaction.14
In response to such concerns and to the medico-legal issues arising from them, in
some countries, such as the United States, it is mandatory to provide consumers
with a Vaccine Information Sheet (VIS) at each medical encounter.11 However, as is
the case with any textual health information, the VIS relies on a standard literacy
level and cannot replace the patient–provider relationship – which forms the basis of
discussions about immunisation. Furthermore, even where such information is
available, many parents will also desire a verbal discussion about risk,15 particularly
those whose educational or cultural background makes written materials less
accessible or less appropriate. Other parents – up to half in some surveys - may
prefer to leave decisions to the health provider, and may request minimal
information about immunisation, other than a reassurance that it is ‘beneficial’ and
‘safe’.16 (BMRB Social Research, Childhood immunisation: Wave 24 report – England
and minority ethnic respondents, Unpublished report, 2004)
But while there is merit in standardising immunisation information and in providing
information through different genres, in many ways such strategies misunderstand
the principles of consent. There is no legal or ethical obligation to provide all
information about a vaccine – only to provide information that is material (of value
or importance) to the patient/consumer or parent.5 And this, in the end, only
becomes clear through interaction between the health provider and patient/parent.
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Indeed, risk communication in a clinical encounter is more than simply a ‘top-down’
supply of information. It is an exchange between a health care provider and
patient/parent, an ongoing discussion built upon trust and the expectation of care,
and an ongoing and integral part of the therapeutic relationship.17 This perspective
acknowledges that both providers and parents have responsibilities. While providers
need to give information and elicit concerns and questions, parents need to
communicate their information needs. In this way, providers can identify parents
with high information needs and pay appropriate attention to a comprehensive risk
discussion if it is needed.
Morally and clinically robust health communication is difficult and time-consuming
and ensuring time for this discussion within the constraints of the contemporary
health care system remains a constant challenge. For this reason, the burden of
informing patients should be shared by a range of health services, not just the
individual immunisation provider. Parents should, and often do, have the
opportunity to receive verbal and written information about immunisation in the
antenatal period, in maternity units, and from community health services. At the
point where parents have contact with vaccine providers, such as in GP waiting
rooms, sufficient materials should be provided prior to a vaccine being given.
Additional efforts to facilitate valid consent in patients/parents with low levels of
literacy and/or numeracy, and for those who do not have English as their primary
language, need to be further developed and made widely available, including
expansion of interpreter services, interactive internet resources, capacityappropriate decision-aids and information sheets in multiple languages.18
Balancing risks and benefits for individuals and communities
The second challenge for consent relates to narrowing risk-benefit profiles. In the
developed world, endemic and highly infectious diseases are now largely controlled
by immunisation; in this environment, new vaccines, while cost-effective as public
health measures, tend to be for diseases that cause comparatively less mortality and
morbidity, such as varicella-zoster.
While, for the most part, health professionals can generally assume that parents
would make decisions to vaccinate their children against diseases such as polio,
pertussis, diphtheria, tetanus, measles, mumps, rubella and Hib based upon a
rational assessment that the benefits of immunisation far outweighed the risk, it is
no longer clear that parents will always make the same decision about newer
vaccines – where the risk–benefit ratio is lower and/or where infection may be
neither very prevalent nor lethal. This same rationale may also hold for older
vaccines when a previously endemic disease such as polio becomes well-controlled
or is declared eliminated from a region such as is currently the case for polio in the
Western Pacific region.19, 20
The possibility that existing or newer vaccines might not offer the same balance of
benefits over risks becomes even more challenging because population-wide
immunisation programs have benefits that are more than simply the sum of the
benefits for vaccinated individuals. For mass immunisation programs, building
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population or ‘herd’ immunity can protect not only those who are immunised, but
those who are not.21 In other words, those who are directly protected by
immunisation shield those who have not been vaccinated from getting the disease,
such as babies too young to have received full protection or those unable to be
vaccinated for medical reasons. People who exempt their child from immunisation,
therefore, may still gain benefits from the widespread immunisation of those around
them without their child facing any of the risks. This is known as the ‘free rider’
problem.22
In many ways, of course, the ‘free rider’ behaviour is understandable, because it is
largely impossible for an individual who decides not to be vaccinated to see the
nearly imperceptible effect that his or her behaviour has on everyone. The problem
is, however, that if enough people choose not to be vaccinated, population immunity
will fall to levels at which outbreaks may occur which will affect those who have not
been vaccinated, and those who have (since no vaccine offers 100% protection).
Thus, while a decision not to vaccinate may be rational for the individual who makes
it, it can lead to harms for whole populations.
In some countries enforcement of immunisation has helped to manage this problem.
In Australia high immunisation coverage has been achieved through a range of nonlegislative strategies including provision of free vaccines under the National
Immunisation Program, financial incentives for immunisation providers and parents,
tracking of coverage through the Australian Childhood Immunisation Register, school
exclusion for unvaccinated children during outbreaks, and education.23
Nevertheless, the question remains of how to ensure valid consent while upholding
population health. While concern has been expressed (at least at a public policy
level) that the public benefit of population immunity is sufficiently great that
communication about the risks of vaccines should be moderated, in fact the limited
existing literature suggests that (1) the few parents who decline vaccination for their
children rarely do so out of a conscious decision to free ride - they simply do not
think vaccines are safe nor effective 24 and (2) parents who lean towards vaccination
are able to take account of information about both individual and societal risk and
benefit and, at least for established vaccines, tend to accept the arguments in favour
of immunisation.22, 25 The problem, however, is that as risk–benefit ratio narrows, it
becomes easier to understand decisions to refuse immunisation, harder to judge
such decisions as morally ‘free riding’, and more difficult to sustain arguments in
favour of mandating such vaccines.26-29 This suggests that clinical decisions about
immunisation will inevitably turn on decisions that are made about immunisation
policy and the support of the community for those decisions. In the final section we
consider why community involvement in, and support for, immunisation policy is
important, what it requires and how it might be achieved.
2. Community consent and vaccine policy
The inclusion of vaccines in a national program has traditionally involved the
deliberations of expert advisory committees who weigh up the benefits of a vaccine
relative to its costs and make recommendations to government.30 These
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deliberations typically consider the following: burden of disease, economic
evaluation, vaccine safety, vaccine effectiveness, feasibility of recommendation,
recommendations of other countries, feasibility of local vaccine production, and
public perceptions.31 Recommendations regarding new vaccines may be made with
varying levels of evidence and scientific certainty, particularly with regards such
factors as correlates of protection, the extent and length of protection, and the risk
of rare but serious reactions.
These systems are comprehensive and appropriate but could be further improved by
more deliberative processes of public engagement. Primarily this is because in every
situation, irrespective of the strength of evidence, policy decisions will involve tradeoffs and value judgements. For example, there are values at play when deciding
whether to vaccinate a group where gains are more marginal but still potentially
important (e.g. rubella and HPV vaccination of boys); in choosing between different
outcomes (e.g. which outcomes of pertussis should be prioritised in choosing the
vaccine schedule), and in decisions about which rates of serious side effects are
acceptable (e.g. the rate of febrile convulsions from influenza vaccination or
intussusception from rotavirus vaccination). Indeed, contrary to popular belief, as
‘evidence’ really refers to ‘fact’ plus ‘value’, it is inevitable that value judgements,
and occasionally political pressure, will come into play in deliberations about
immunisation policy.32 Furthermore, as governments are empowered to make
decisions in terms of the public interest it is also inevitable that groups of experts or
sometimes individuals will be the ones who make judgements about what outcomes
should be prioritised and what level of risk is acceptable.
Because the harms and benefits of vaccines are borne by the entire community and
decisions about vaccines are often made under conditions of epidemiological
uncertainty, in ethical terms a strong case can be made for including the community
in deliberations about policy and practice. In recent years, this case has been
increasingly recognised and a range of strategies have been used to achieve it,
including lay membership of expert panels, community surveys, broad community
engagement processes, public meetings, citizens’ juries and consensus
conferences.33-36
Each of these approaches has advantages and disadvantages. Lay membership of
expert panels is a common approach in immunisation policy development. Here, an
individual becomes the focal point through which the wider community’s values and
perspective are channelled. That individual will inevitably have specific interests and
perspectives and they are usually not sufficiently resourced to gauge, and then
represent, the views of the entire community. Social research methods, such as
focus groups, surveys and choice experiments, can provide more representative
information about likely or actual public responses to policy initiatives, but may
reflect only uninformed community opinion about matters that are scientifically and
socially complex. Community consultation through submissions and committees of
inquiry can collect views from a more informed public, but tend to prejudice the
views of a vocal minority. While deliberative processes, such as consensus
conferences and citizens’ juries, may provide inputs into policy decisions that are
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more informed and more reflective of community values, they also are open to the
criticism of selection bias and generalisability and are resource intensive.37, 38 Despite
such drawbacks, however, the development of immunisation policy, particularly in
areas where the trade-off between public good and personal choice is stark, would
surely benefit from community participation via processes of deliberative
democracy.
Finally, listening and valuing the input of citizens will become increasingly important
as vaccines continue to attain their success and we see a growing focus on vaccine
safety. For it is in such processes that governments can better understand lay
perspectives, build mutual trust and engender a more productive conversation that
works towards the ultimate goal of public health and wellbeing.
Conclusion
Recent developments in childhood immunisation programs present unique
challenges – the number of vaccines on offer continue to increase, while at the same
time the risk–benefit ratios of some vaccines become increasingly narrow. In this
setting it is increasingly difficult to balance competing demands – public health
imperatives for high uptake of immunisation, requirements for valid consent, and
respect for personal choice. But there is no option but to address these challenges as
consent remains the cornerstone of respect for autonomy in health care and is one
of the foundations upon which public trust in immunisation is maintained.
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